David Hung, Founder, President, CEO & Chairman, highlighted that "2025 was a pivotal year for Nuvation Bio" due to the full U.S. FDA approval of IBTROZI for advanced ROS1-positive non-small cell lung ...

As Samsung Biologics’ contract manufacturing business continues to fire on all cylinders, the CDMO has earned a unique distinction among Korean biopharmas following a highly profitable 2025. Last year ...

Successfully started 216 patients on IBTROZI ® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025 Preliminary IBTROZI net ...

Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round attracted prominent leaders in AI and ...

The consensus estimate for Q4 2025 revenue is $21.05 million, and the earnings are expected to come in at -$0.18 per share. The full year 2025's revenue is expected to be $80.45 million, and the ...

The FBS regular season is in the books and 29 first-year coaches have finished their debut seasons. Here’s a recap of how they did, ranking their performances from top to bottom. Jerry Mack won the ...

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials ...

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 ...

Biotechs with drugs on the market were eager to share their fourth quarter revenue with investors as the J.P. Morgan 2026 Healthcare Conference kicked off today with some even brave enough to give ...